191 related articles for article (PubMed ID: 33853825)
1. Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens.
Kines RC; Thompson CD; Spring S; Li Z; de Los Pinos E; Monks S; Schiller JT
Cancer Immunol Res; 2021 Jun; 9(6):693-706. PubMed ID: 33853825
[TBL] [Abstract][Full Text] [Related]
2.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
3. Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors.
Nagaya T; Friedman J; Maruoka Y; Ogata F; Okuyama S; Clavijo PE; Choyke PL; Allen C; Kobayashi H
Cancer Immunol Res; 2019 Mar; 7(3):401-413. PubMed ID: 30683733
[TBL] [Abstract][Full Text] [Related]
4. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors.
Huis In 't Veld RV; Ma S; Kines RC; Savinainen A; Rich C; Ossendorp F; Jager MJ
Cancer Immunol Immunother; 2023 Jul; 72(7):2405-2422. PubMed ID: 36997666
[TBL] [Abstract][Full Text] [Related]
6. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
7. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
8. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
9. Virus-Like Particles Presenting the FGF-2 Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice.
Shu C; Sun P; Xie H; Huang W; Qi J; Ma Y
Int J Nanomedicine; 2020; 15():1983-1996. PubMed ID: 32308382
[TBL] [Abstract][Full Text] [Related]
10. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
11. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy.
Koerner J; Horvath D; Herrmann VL; MacKerracher A; Gander B; Yagita H; Rohayem J; Groettrup M
Nat Commun; 2021 May; 12(1):2935. PubMed ID: 34006895
[TBL] [Abstract][Full Text] [Related]
12.
Baniel CC; Heinze CM; Hoefges A; Sumiec EG; Hank JA; Carlson PM; Jin WJ; Patel RB; Sriramaneni RN; Gillies SD; Erbe AK; Schwarz CN; Pieper AA; Rakhmilevich AL; Sondel PM; Morris ZS
Front Immunol; 2020; 11():1610. PubMed ID: 32849544
[TBL] [Abstract][Full Text] [Related]
13. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.
Tseng CW; Hung CF; Alvarez RD; Trimble C; Huh WK; Kim D; Chuang CM; Lin CT; Tsai YC; He L; Monie A; Wu TC
Clin Cancer Res; 2008 May; 14(10):3185-92. PubMed ID: 18483387
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
19. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak AK; Robinson BW; Lake RA
Cancer Res; 2003 Aug; 63(15):4490-6. PubMed ID: 12907622
[TBL] [Abstract][Full Text] [Related]
20. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.
Nierkens S; den Brok MH; Roelofsen T; Wagenaars JA; Figdor CG; Ruers TJ; Adema GJ
PLoS One; 2009 Dec; 4(12):e8368. PubMed ID: 20020049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
